|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The present study was designed to assess the contribution of these SNPs to disease progression in patients with chronic hepatitis C. The study enrolled 220 Japanese patients with chronic hepatitis C. Three SNPs, -1195 COX-2, PNPLA3 and IL28B (rs8099917), were genotyped in order to analyze their association with hepatic fibrosis and inflammation.
|
22863264 |
2012 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A genetic variant in adiponutrin (PNPLA3) gene, rs738409 C/G, is associated with steatosis, severity, and progression of liver fibrosis in CHC patients, and predicts treatment outcome in difficult-to-cure HCV-infected patients with advanced fibrosis.
|
26389885 |
2015 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The common PNPLA3 (adiponutrin) variant, p.I148M, was identified as a genetic determinant of liver fibrosis.
|
24152445 |
2013 |
|
Fibrosis, Liver
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In multivariate analysis, the predictive variables for advanced liver fibrosis were age (≥60) (P=0.005), sex (female) (P=0.004) and rs 738409 PNPLA3 polymorphism (P=0.01); body mass index (BMI) and LFC were not associated with liver fibrosis.
|
21745307 |
2011 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Presence of minor allele (G) of PNPLA3 was also associated with moderate/severe steatosis (≥33%) both in patients with (OR: 2.405 [CI95%: 1.220-4.744], P=0.011) and without MetS (OR: 2.481 [CI95%: 1.172-5.250], P=0.018), but was only associated with NASH (OR: 2.002 [CI95%: 1.062-3.772], P=0.032) and liver fibrosis (OR: 2.646 [CI95%: 1.299-5.389], P=0.007) in patients without MetS.
|
27908400 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
PNPLA3 p.148M/M genotype was negatively associated with SVR and early viral kinetics independently of steatosis, albeit only in difficult-to-cure G1/4 patients with advanced fibrosis, whereas stratification for the p.148M/M PNPLA3 genotype unmasked an association between IL28B CC genotype and more severe liver fibrosis.
|
22530607 |
2012 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Allelic variation (rs738409C→G) in adiponutrin (patatin-like phospholipase domain-containing protein 3, PNPLA3) has been associated with hepatic steatosis and liver fibrosis.
|
23418085 |
2013 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Advanced liver fibrosis was neither associated with PNPLA3 (p = 0.253) nor IL28B-genotype (p = 0.628), but with HCV-GT3 (p = 0.003), higher BMI (p = 0.008) and higher age (p = 0.007).
|
26599080 |
2015 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fetuin B is independently and negatively associated with non-invasive markers of liver fibrosis and PNPLA3 status in NAFLD patients but does not show a correlation with the hepatic lipid content.
|
28914407 |
2017 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
These genetic variations also did not mediate the effect of <i>PNPLA3 rs738409</i> SNP for liver developing liver fibrosis or liver cirrhosis.
|
30875804 |
2019 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
The objectives of this study were to determine the association between PNPLA3 and liver fibrosis severity, HCC risk, and HCC prognosis among patients with liver disease.
|
24445574 |
2014 |
|
Fibrosis, Liver
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, we provide evidence to indicate that PNPLA3-mediated retinol release may protect against liver fibrosis by inducing a specific signature of proteins involved in extracellular matrix remodelling.
|
27742777 |
2016 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
PNPLA3 G was also associated with increased levels of ALT, except in participants with Dominican and South American backgrounds, and with liver fibrosis.
|
30743004 |
2019 |
|
Fibrosis, Liver
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In patients with nonalcoholic steatohepatitis (NASH), PNPLA3 GG compared to CC was associated with higher AST levels [38.4±25.3 versus 36.7±40.1IU/L, p=0.0395)] and with the presence of liver fibrosis (≥F2 fibrosis, p=0.0272).
|
31054980 |
2020 |